- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:42 | YD Bio Limited: YD Bio Business Partner EG Biomed Achieves CAP Accreditation, Advancing U.S. Clinical Testing Capabilities | 73 | GlobeNewswire (Europe) | Taipei, Taiwan, Oct. 10, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and... ► Artikel lesen | |
| 01.10. | YD Bio Limited reports 1H results | 2 | Seeking Alpha | ||
| YD BIO Aktie jetzt für 0€ handeln | |||||
| 30.09. | YD Bio Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 26.09. | YD Bio meldet COO-Rücktritt und plant Registrierung öffentlicher Optionsscheine | 1 | Investing.com Deutsch | ||
| 23.09. | YD Bio Ltd - F-1, Registration statement for certain foreign private issuers | 1 | SEC Filings | ||
| 19.09. | YD Bio Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 08.09. | YD Biopharma Ltd - 15-15D, Suspension of duty to report | 2 | SEC Filings | ||
| 28.08. | YD Bio Limited Announces Closing of Business Combination and Listing on the Nasdaq Global Market | 248 | GlobeNewswire (Europe) | Strategic Move Positions YD Bio Limited for Accelerated Innovation and Market ExpansionTrading of common stock and warrants of the new public company, YD Bio Limited, is expected to commence on the... ► Artikel lesen | |
| 20.08. | YD Bio Ltd - 8-A12B, Registration of securities | 2 | SEC Filings | ||
| 15.08. | Breeze Holdings Acquisition Corp. Shareholders Approve Business Combination with YD Biopharma Limited | 186 | GlobeNewswire (Europe) | Transaction Expected to Close in the Coming Days Combined Company to be Named YD Bio Limited and Expectedto Trade on Nasdaq Under Ticker Symbol "YDES" IRVING, Texas, Aug. 15, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| 15.08. | YD Bio Ltd - 6-K, Report of foreign issuer | 3 | SEC Filings |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,470 | -1,56 % | Sysmex, QIAGEN Announce Exclusive Distribution Partnership For Diagnostic Products In Japan | TOKYO (dpa-AFX) - Sysmex Corporation (SSMXY.PK) and QIAGEN K.K., the Japanese subsidiary of QIAGEN N.V., announced on Wednesday that they have entered into a partnership for clinical diagnostic... ► Artikel lesen | |
| EVOTEC | 6,698 | -0,86 % | Adidas, Bechtle, Bitcoin Group, Evotec, Renk, Ströer - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| BIONTECH | 87,50 | -3,15 % | BioNTech Aktie zeigt Stärke: Es wird spannend! | Seit dem letzten 4investors.de-Chartcheck zur BioNTech Aktie hat sich einiges getan. Der Aktienkurs des Mainzer Biotech-Konzerns ist an der NASDAQ um rund 9 Dollar gestiegen, hat die 20- und 50-Tage-Linie... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,375 | -8,98 % | Recursion Pharmaceuticals (RXRX) Climbs 16% Ahead of AI Conference | ||
| VIKING THERAPEUTICS | 29,170 | -3,62 % | Why Shares in Viking Therapeutics Surged This Week | ||
| APOGEE THERAPEUTICS | 53,23 | +0,04 % | Apogee Therapeutics sichert sich 323,3 Mio. US-Dollar durch Aktienplatzierung an der NASDAQ | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 10,150 | +7,86 % | Oppenheimer senkt Kursziel für Moonlake Immunotherapeutics nach durchwachsenen Studienergebnissen | ||
| INTELLIA THERAPEUTICS | 20,700 | -6,04 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| JYONG BIOTECH | 56,47 | +5,61 % | Jyong Biotech Ltd.: Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS-8 for Prostate Cancer Prevention | New Taipei City, Taiwan, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company", "Jyong Biotech"), a science-driven biotechnology company based in Taiwan committed to... ► Artikel lesen | |
| TOURMALINE BIO | 47,885 | +0,09 % | Novartis Pharma AG: Novartis announces commencement of tender offer to acquire Tourmaline Bio | Basel, September 29, 2025 - Novartis today announced that Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis ("Purchaser"), has commenced a tender offer... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 21,700 | -4,19 % | UBS bestätigt Kaufempfehlung für Summit Therapeutics vor ESMO-Daten | ||
| ARCELLX | 88,99 | +0,64 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| BEAM THERAPEUTICS | 25,920 | -7,00 % | Jefferies stuft Beam Therapeutics auf "Buy": Kommende Katalysatoren im Fokus | ||
| CRISPR THERAPEUTICS | 62,00 | -4,62 % | CRISPR Therapeutics AG: CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe | ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based... ► Artikel lesen | |
| 89BIO | 14,805 | -0,30 % | Roche Launches Tender Offer To Acquire 89bio For $14.50/shr Plus CVR | SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY, RO.SW, ROG.SW) announced that it has launched a tender offer to acquire all outstanding common shares of 89bio, Inc. (ETNB). The offer includes... ► Artikel lesen |
YD BIO LIMITED gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -1,510 (-7,94 %) liegt der Kurs bei 17,500 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu YD BIO LIMITED finden Sie auf Wallstreet Online.